{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:18:50Z","timestamp":1793823530895,"version":"4.6.1"},"reference-count":130,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011151","name":"American Academy of Ophthalmology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.survophthal.2026.03.012","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T17:19:30Z","timestamp":1773854370000},"page":"1505-1516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacologic principles behind eye drop dosing: From pharmacokinetics to clinical practice"],"prefix":"10.1016","volume":"71","author":[{"given":"Luca","family":"Lucchino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Chiorrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Semeraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Drago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1191-4989","authenticated-orcid":false,"given":"Mariantonia","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.survophthal.2026.03.012_bib1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","article-title":"Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues","volume":"61","author":"Lai","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.survophthal.2026.03.012_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/sstr.202570006","article-title":"Design of highly adhesive urchin-like gold nanostructures for effective topical drug administration and symptomatic relief of corneal dryness","volume":"6","author":"Ghosh","year":"2025","journal-title":"Small Struct"},{"key":"10.1016\/j.survophthal.2026.03.012_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2021.128469","article-title":"Carbonized nanogels for simultaneous antibacterial and antioxidant treatment of bacterial keratitis","volume":"411","author":"Lin","year":"2021","journal-title":"Chem Eng J"},{"key":"10.1016\/j.survophthal.2026.03.012_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119961","article-title":"Dually functional hollow ceria nanoparticle platform for intraocular drug delivery: a push beyond the limits of static and dynamic ocular barriers toward glaucoma therapy","volume":"243","author":"Luo","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.survophthal.2026.03.012_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202302174","article-title":"Poly(l-histidine)-mediated on-demand therapeutic delivery of roughened ceria nanocages for treatment of chemical eye injury","volume":"10","author":"Yang","year":"2023","journal-title":"Adv Sci"},{"issue":"6","key":"10.1016\/j.survophthal.2026.03.012_bib6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-016-0339-2","article-title":"A comprehensive insight on ocular pharmacokinetics","volume":"6","author":"Agrahari","year":"2016","journal-title":"Drug Deliv Transl Res"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.012_bib7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1517\/17425247.3.2.275","article-title":"Ocular drug delivery","volume":"3","author":"Ghate","year":"2006","journal-title":"Expert Opin Drug Deliv"},{"issue":"11","key":"10.1016\/j.survophthal.2026.03.012_bib8","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","article-title":"Challenges and obstacles of ocular pharmacokinetics and drug delivery","volume":"58","author":"Urtti","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/14712598.3.1.45","article-title":"Drug delivery to the retina: challenges and opportunities","volume":"3","author":"Duvvuri","year":"2003","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"10.1016\/j.survophthal.2026.03.012_bib10","doi-asserted-by":"crossref","first-page":"8718","DOI":"10.1167\/iovs.11-7871","article-title":"Corneal penetration of topical and subconjunctival bevacizumab","volume":"52","author":"Dastjerdi","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.survophthal.2026.03.012_bib11","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: the good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"10.1016\/j.survophthal.2026.03.012_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106113","article-title":"What is the optimal loading dose of broad-spectrum \u03b2-lactam antibiotics in septic patients?","volume":"56","author":"Delattre","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.survophthal.2026.03.012_bib13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00003226-200404000-00007","article-title":"Concentrations of levofloxacin, ofloxacin, and ciprofloxacin in human corneal stromal tissue and aqueous humor after topical administration","volume":"23","author":"Healy","year":"2004","journal-title":"Cornea"},{"issue":"7","key":"10.1016\/j.survophthal.2026.03.012_bib14","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1167\/iovs.08-3201","article-title":"Concentration and bioavailability of ciprofloxacin and teicoplanin in the cornea","volume":"50","author":"Kaye","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.survophthal.2026.03.012_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/jop.1986.2.365","article-title":"Effects of eyelid closure and nasolacrimal duct occlusion on the systemic absorption of ocular timolol in human subjects","volume":"2","author":"Kaila","year":"1986","journal-title":"J Ocul Pharm"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archopht.123.1.39","article-title":"Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous","volume":"123","author":"Hariprasad","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/bjo.88.1.22","article-title":"I. Human corneal stromal tissue concentration after consecutive doses of topically applied 3.3% vancomycin","volume":"88","author":"Ben Simon","year":"2004","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2026.03.012_bib18","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/OPX.0000000000000692","article-title":"Effect of corneal thickness on the penetration of topical vancomycin","volume":"92","author":"Spierer","year":"2015","journal-title":"Optom Vis Sci"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.012_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/pathogens10020165","article-title":"The minimum inhibitory concentration of antibiotics: methods, interpretation, clinical relevance","volume":"10","author":"Kowalska-Krochmal","year":"2021","journal-title":"Pathogens"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2022-001002","article-title":"Potential new fluoroquinolone treatments for suspected bacterial keratitis","volume":"7","author":"Herbert","year":"2022","journal-title":"BMJ Open Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2026.03.012_bib21","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/OPX.0000000000001768","article-title":"Vitro antibiotic resistance among bacteria from the cornea in the ARMOR study","volume":"98","author":"Thomas","year":"2021","journal-title":"Optom Vis Sci"},{"issue":"5","key":"10.1016\/j.survophthal.2026.03.012_bib22","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1167\/iovs.09-4638","article-title":"Minimum inhibitory concentrations of standard and novel antimicrobials for isolates from bacterial keratitis","volume":"51","author":"Sueke","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2026.03.012_bib23","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.9419","article-title":"Biofilm modelling on the contact lenses and comparison of the in vitro activities of multipurpose lens solutions and antibiotics","volume":"8","author":"Dosler","year":"2020","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkae380","article-title":"Bactericidal versus bacteriostatic antibacterials: clinical significance, differences and synergistic potential in clinical practice","volume":"80","author":"Ishak","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.survophthal.2026.03.012_bib25","series-title":"Clinical Pharmacy Education, Practice and Research","first-page":"425","article-title":"Chapter 30 - therapeutic drug monitoring","author":"Junaid","year":"2019"},{"issue":"12","key":"10.1016\/j.survophthal.2026.03.012_bib26","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1097\/TP.0000000000002938","article-title":"High-risk corneal transplantation: recent developments and future possibilities","volume":"103","author":"Armitage","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.survophthal.2026.03.012_bib27","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update","volume":"55","author":"Mouton","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.survophthal.2026.03.012_bib28","first-page":"401","article-title":"Basic concepts of pharmacokinetic\/pharmacodynamic (PK\/PD) modelling","volume":"35","author":"Meibohm","year":"1997","journal-title":"Int J Clin Pharm Ther"},{"issue":"7","key":"10.1016\/j.survophthal.2026.03.012_bib29","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/01.tp.0000285489.91595.13","article-title":"The immunobiology of corneal transplantation","volume":"84","author":"Williams","year":"2007","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.survophthal.2026.03.012_bib30","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1086\/323748","article-title":"Fluoroquinolone pharmacodynamics","volume":"33","author":"Drusano","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.012_bib31","first-page":"S127","article-title":"Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones","volume":"41","author":"Owens","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.survophthal.2026.03.012_bib32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/00003088-199427050-00005","article-title":"Pharmacokinetic contributions to postantibiotic effects","volume":"27","author":"Zhanel","year":"1994","journal-title":"Clin Pharm"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.012_bib33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/00365510601034736","article-title":"Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects","volume":"67","author":"Nieminen","year":"2007","journal-title":"Scand J Clin Lab Invest"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.012_bib34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1542-0124(12)70157-X","article-title":"Assessment of tear film dynamics: quantification approach","volume":"3","author":"Tomlinson","year":"2005","journal-title":"Ocul Surf"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib35","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/bjo.2007.121533","article-title":"Fluorophotometric measurement of the precorneal residence time of topically applied hyaluronic acid","volume":"92","author":"Mochizuki","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2026.03.012_bib36","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1167\/iovs.14-16313","article-title":"The effects of increasing ocular surface stimulation on blinking and tear secretion","volume":"56","author":"Wu","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2026.03.012_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2022.954771","article-title":"Topical ophthalmic administration: can a drug instilled onto the ocular surface exert an effect at the back of the eye?","volume":"2","author":"Del Amo","year":"2022","journal-title":"Front Drug Deliv"},{"issue":"3","key":"10.1016\/j.survophthal.2026.03.012_bib38","first-page":"264","article-title":"Determination of tear volume and tear flow","volume":"5","author":"Mishima","year":"1966","journal-title":"Invest Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2026.03.012_bib39","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/OPX.0000000000002172","article-title":"Comparison of eye drop retention time using fluorophotometry in three commercially available lubricant eye drops","volume":"101","author":"Jia","year":"2024","journal-title":"Optom Vis Sci"},{"issue":"3","key":"10.1016\/j.survophthal.2026.03.012_bib40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1208\/s12249-021-01977-0","article-title":"Review of approaches for increasing ophthalmic bioavailability for eye drop formulations","volume":"22","author":"Lanier","year":"2021","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.012_bib41","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10792-016-0280-x","article-title":"Evaluation of physical properties and dose equivalency of generic versus branded latanoprost formulations","volume":"37","author":"Angmo","year":"2017","journal-title":"Int Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2026.03.012_bib42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1529-1839(04)70035-4","article-title":"pH stability of ophthalmic solutions","volume":"75","author":"Garcia-Valldecabres","year":"2004","journal-title":"Optometry"},{"key":"10.1016\/j.survophthal.2026.03.012_bib43","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.addr.2017.12.006","article-title":"Efficacy and safety concerns over the use of mucus modulating agents for drug delivery using nanoscale systems","volume":"124","author":"Chater","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.012_bib44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5497\/wjp.v2.i2.47","article-title":"Ocular drug delivery systems: an overview","volume":"2","author":"Patel","year":"2013","journal-title":"World J Pharm"},{"key":"10.1016\/j.survophthal.2026.03.012_bib45","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.2147\/OPTH.S95242","article-title":"Tear film osmolarity and dry eye disease: a review of the literature","volume":"9","author":"Potvin","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib46","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0169-409X(95)00014-X","article-title":"Ocular inserts for topical delivery","volume":"16","author":"Saettone","year":"1995","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"10.1016\/j.survophthal.2026.03.012_bib47","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1046\/j.1440-1681.2000.03288.x","article-title":"Biopharmaceutical considerations in topical ocular drug delivery","volume":"27","author":"Davies","year":"2000","journal-title":"Clin Exp Pharm Physiol"},{"key":"10.1016\/j.survophthal.2026.03.012_bib48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejpb.2017.03.006","article-title":"Cyclosporine A delivery to the eye: a comprehensive review of academic and industrial efforts","volume":"117","author":"Lallemand","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.012_bib49","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/pharmaceutics13020207","article-title":"Formulation considerations for the management of dry eye disease","volume":"13","author":"Agarwal","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib50","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s11671-025-04234-6","article-title":"Ocular drug delivery systems based on nanotechnology: a comprehensive review for the treatment of eye diseases","volume":"20","author":"Bairagi","year":"2025","journal-title":"Discov Nano"},{"issue":"3","key":"10.1016\/j.survophthal.2026.03.012_bib51","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1124\/jpet.119.256933","article-title":"Ocular drug delivery: present innovations and future challenges","volume":"370","author":"Gote","year":"2019","journal-title":"J Pharm Exp Ther"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib52","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1167\/iovs.65.1.4","article-title":"Transmembrane protein CMTM6 alleviates ocular inflammatory response and improves corneal epithelial barrier function in experimental dry eye","volume":"65","author":"Zhou","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.survophthal.2026.03.012_bib53","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1021\/js9504189","article-title":"Effect of benzalkonium chloride\/EDTA on the ocular bioavailability of ketorolac tromethamine following ocular instillation to normal and de-epithelialized corneas of rabbits","volume":"85","author":"Madhu","year":"1996","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.survophthal.2026.03.012_bib54","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1080\/17425255.2016.1209481","article-title":"Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK)","volume":"12","author":"Aguayo Bonniard","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"10.1016\/j.survophthal.2026.03.012_bib55","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/jop.2010.0111","article-title":"vitro comparative toxicology of polyquad-preserved and benzalkonium chloride-preserved travoprost\/timolol fixed combination and latanoprost\/timolol fixed combination","volume":"27","author":"Brignole-Baudouin","year":"2011","journal-title":"J Ocul Pharm Ther"},{"issue":"4","key":"10.1016\/j.survophthal.2026.03.012_bib56","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1167\/iovs.11-8775","article-title":"Corneal neurotoxicity due to topical benzalkonium chloride","volume":"53","author":"Sarkar","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2026.03.012_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2024.151997","article-title":"Carbon-in-carbon: hybrid carbonized nanomaterials with multifunctional activities for the treatment of endophthalmitis","volume":"491","author":"Jian","year":"2024","journal-title":"Chem Eng J"},{"issue":"24","key":"10.1016\/j.survophthal.2026.03.012_bib58","doi-asserted-by":"crossref","first-page":"25118","DOI":"10.1021\/acsnano.3c07817","article-title":"Unveiling the power of gabapentin-loaded nanoceria with multiple therapeutic capabilities for the treatment of dry eye disease","volume":"17","author":"Yang","year":"2023","journal-title":"ACS Nano"},{"issue":"11","key":"10.1016\/j.survophthal.2026.03.012_bib59","doi-asserted-by":"crossref","first-page":"5447","DOI":"10.7150\/thno.54525","article-title":"Harnessing the tunable cavity of nanoceria for enhancing Y-27632-mediated alleviation of ocular hypertension","volume":"11","author":"Luo","year":"2021","journal-title":"Theranostics"},{"issue":"24","key":"10.1016\/j.survophthal.2026.03.012_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201900702","article-title":"Dendritic effects of injectable biodegradable thermogels on pharmacotherapy of inflammatory glaucoma-associated degradation of extracellular matrix","volume":"8","author":"Nguyen","year":"2019","journal-title":"Adv Health Mater"},{"issue":"8","key":"10.1016\/j.survophthal.2026.03.012_bib61","article-title":"Advancing ocular medication delivery with nano-engineered solutions: a comprehensive review of innovations, obstacles, and clinical impact","volume":"16","author":"Rajan","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.survophthal.2026.03.012_bib62","article-title":"Harnessing light: synthesis, mechanisms, and pre-clinical biomedical applications of stimuli-responsive multiscale composites","volume":"35","author":"Ghosh","year":"2025","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.survophthal.2026.03.012_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.pmatsci.2025.101634","article-title":"Hollow nanoarchitectures: materials engineering, nanochemistry, and biomedical applications","volume":"158","author":"Ghosh","year":"2026","journal-title":"Prog Mater Sci"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib64","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1021\/acsnano.2c05824","article-title":"Highly retina-permeating and long-acting resveratrol\/metformin nanotherapeutics for enhanced treatment of macular degeneration","volume":"17","author":"Nguyen","year":"2023","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib65","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40360-025-00934-y","article-title":"In-situ gel bases ocular delivery system of Ganciclovir, in-vivo and in-vitro investigation","volume":"26","author":"Paul","year":"2025","journal-title":"BMC Pharm Toxicol"},{"issue":"Pt 2","key":"10.1016\/j.survophthal.2026.03.012_bib66","article-title":"Tiny tools, big vision: a minireview on carbonized nanomaterials in ophthalmology","volume":"388","author":"Unnikrishnan","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.survophthal.2026.03.012_bib67","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.preteyeres.2012.10.004","article-title":"A contemporary concept of the blood-aqueous barrier","volume":"32","author":"Freddo","year":"2013","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib68","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12951-023-01992-2","article-title":"Nanotechnology-based ocular drug delivery systems: recent advances and future prospects","volume":"21","author":"Li","year":"2023","journal-title":"J Nanobiotechnology"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib69","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2016-000047","article-title":"Empirical treatment of bacterial keratitis: an international survey of corneal specialists","volume":"2","author":"Austin","year":"2017","journal-title":"BMJ Open Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2026.03.012_bib70","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1124\/dmd.116.069369","article-title":"Drug transport by the blood-aqueous humor barrier of the eye","volume":"44","author":"Lee","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.survophthal.2026.03.012_bib71","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1001\/archopht.126.11.1572","article-title":"Microbial biofilms in ophthalmology and infectious disease","volume":"126","author":"Behlau","year":"2008","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2026.03.012_bib72","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00003226-200304000-00021","article-title":"Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology","volume":"22","author":"Cursiefen","year":"2003","journal-title":"Cornea"},{"issue":"Pt 1","key":"10.1016\/j.survophthal.2026.03.012_bib73","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/eye.1995.16","article-title":"Biofilm-related infections in ophthalmology","volume":"9","author":"Elder","year":"1995","journal-title":"Eye (Lond)"},{"issue":"6","key":"10.1016\/j.survophthal.2026.03.012_bib74","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.3390\/microorganisms11061614","article-title":"Microbial biofilm: a review on formation, infection, antibiotic resistance, control measures, and innovative treatment","volume":"11","author":"Sharma","year":"2023","journal-title":"Microorganisms"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib75","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s44259-024-00046-3","article-title":"Mechanisms of antimicrobial resistance in biofilms","volume":"2","author":"Liu","year":"2024","journal-title":"NPJ Antimicrob Resist"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib76","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0966-842X(00)01913-2","article-title":"Mechanisms of biofilm resistance to antimicrobial agents","volume":"9","author":"Mah","year":"2001","journal-title":"Trends Microbiol"},{"issue":"3","key":"10.1016\/j.survophthal.2026.03.012_bib77","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/ceo.14377","article-title":"Antimicrobial resistance in ocular infection: a review","volume":"52","author":"Cabrera-Aguas","year":"2024","journal-title":"Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4014\/jmb.2010.10021","article-title":"Mechanisms and control strategies of antibiotic resistance in pathological biofilms","volume":"31","author":"Luo","year":"2021","journal-title":"J Microbiol Biotechnol"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib79","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1381612820666140905114627","article-title":"Quorum sensing inhibitors as anti-biofilm agents","volume":"21","author":"Brackman","year":"2015","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.survophthal.2026.03.012_bib80","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41579-023-00905-2","article-title":"Drug delivery strategies for antibiofilm therapy","volume":"21","author":"Choi","year":"2023","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib81","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1186\/s12879-025-11608-9","article-title":"Evaluation of hybrid capture-based targeted and metagenomic next-generation sequencing for pathogenic microorganism detection in infectious keratitis","volume":"25","author":"Lan","year":"2025","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2006.10.001","article-title":"Infectious keratitis following keratoplasty","volume":"52","author":"Vajpayee","year":"2007","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.012_bib83","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejpb.2012.02.014","article-title":"Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies","volume":"81","author":"Di Tommaso","year":"2012","journal-title":"Eur J Pharm Biopharm"},{"issue":"9","key":"10.1016\/j.survophthal.2026.03.012_bib84","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/ICO.0000000000002827","article-title":"Use of topical cyclosporine 0.1% in therapeutic penetrating keratoplasty for fungal keratitis","volume":"41","author":"Chatterjee","year":"2022","journal-title":"Cornea"},{"issue":"5","key":"10.1016\/j.survophthal.2026.03.012_bib85","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.3390\/jcm9051270","article-title":"Topical VEGF-C\/D inhibition prevents lymphatic vessel ingrowth into cornea but does not improve corneal graft survival","volume":"9","author":"Salabarria","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.survophthal.2026.03.012_bib86","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jtos.2021.12.001","article-title":"Fungal keratitis: a review of clinical presentations, treatment strategies and outcomes","volume":"24","author":"Sharma","year":"2022","journal-title":"Ocul Surf"},{"issue":"11","key":"10.1016\/j.survophthal.2026.03.012_bib87","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/ICO.0000000000003340","article-title":"Steroids in the management of infectious keratitis","volume":"42","author":"Keenan","year":"2023","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2026.03.012_bib88","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ajo.2025.05.040","article-title":"TFOS DEWS III: diagnostic methodology","volume":"279","author":"Stapleton","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.03.012_bib89","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ajo.2025.05.039","article-title":"TFOS collaborator group. TFOS DEWS III: management and therapy","volume":"279","author":"Jones","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.03.012_bib90","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ajo.2025.05.040","article-title":"TFOS DEWS III: digest","volume":"279","author":"Stapleton","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.012_bib91","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1542-0124(12)70149-0","article-title":"Character of ocular surface mucins and their alteration in dry eye disease","volume":"2","author":"Gipson","year":"2004","journal-title":"Ocul Surf"},{"issue":"14","key":"10.1016\/j.survophthal.2026.03.012_bib92","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.17-23756","article-title":"The ocular surface glycocalyx and its alteration in dry eye disease: a review","volume":"59","author":"Uchino","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib93","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0002-9440(10)62232-8","article-title":"Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye","volume":"166","author":"Pflugfelder","year":"2005","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.survophthal.2026.03.012_bib94","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0161-6420(92)31879-2","article-title":"Corneal epithelial permeability of dry eyes before and after treatment with artificial tears","volume":"99","author":"G\u00f6bbels","year":"1992","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.survophthal.2026.03.012_bib95","doi-asserted-by":"crossref","first-page":"P87","DOI":"10.1016\/j.ophtha.2023.12.035","article-title":"Bacterial keratitis preferred practice pattern\u00ae","volume":"131","author":"Rhee","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2026.03.012_bib96","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jtos.2021.08.013","article-title":"Urgent unmet needs in the care of bacterial keratitis: an evidence-based synthesis","volume":"28","author":"Ung","year":"2023","journal-title":"Ocul Surf"},{"issue":"5","key":"10.1016\/j.survophthal.2026.03.012_bib97","first-page":"881","article-title":"Comparative bioavailability and efficacy of fortified topical tobramycin","volume":"28","author":"Gilbert","year":"1987","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.survophthal.2026.03.012_bib98","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jcjo.2012.09.001","article-title":"Fluoroquinolones or fortified antibiotics for treating bacterial keratitis: systematic review and meta-analysis of comparative studies","volume":"47","author":"Hanet","year":"2012","journal-title":"Can J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.012_bib99","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/00003226-200003000-00014","article-title":"Effect of fortified antibiotic solutions on corneal epithelial wound healing","volume":"19","author":"Lin","year":"2000","journal-title":"Cornea"},{"issue":"11","key":"10.1016\/j.survophthal.2026.03.012_bib100","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/bjo.76.11.681","article-title":"Pharmacokinetics of ophthalmic corticosteroids","volume":"76","author":"McGhee","year":"1992","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.012_bib101","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0163-7258(82)90009-2","article-title":"Dosage regimen design","volume":"17","author":"DeVane","year":"1982","journal-title":"Pharmacol & Ther"},{"issue":"4","key":"10.1016\/j.survophthal.2026.03.012_bib102","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0924-8579(02)00020-1","article-title":"Can PK\/PD be used in everyday clinical practice","volume":"19","author":"Scaglione","year":"2002","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"10.1016\/j.survophthal.2026.03.012_bib103","first-page":"1811","article-title":"Aminoglycosides: a practical review","volume":"58","author":"Gonzalez","year":"1998","journal-title":"Am Fam Physician"},{"issue":"6","key":"10.1016\/j.survophthal.2026.03.012_bib104","doi-asserted-by":"crossref","first-page":"a027029","DOI":"10.1101\/cshperspect.a027029","article-title":"Aminoglycosides: an Overview","volume":"6","author":"Krause","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib105","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00003226-200201000-00011","article-title":"Residence time of netilmicin in tears","volume":"21","author":"Scuderi","year":"2002","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2026.03.012_bib106","doi-asserted-by":"crossref","DOI":"10.1111\/j.1469-0691.1998.tb00692.x","article-title":"Pharmacokinetics and pharmacodynamics of fluoroquinolones","volume":"4","author":"Drusano","year":"1998","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.012_bib107","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.survophthal.2004.01.005","article-title":"Fluoroquinolones: mechanism of action, classification, and development of resistance","volume":"49","author":"Blondeau","year":"2004","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.012_bib108","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3201\/eid0702.010239","article-title":"Emerging mechanisms of fluoroquinolone resistance","volume":"7","author":"Hooper","year":"2001","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib109","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1086\/514622","article-title":"The pharmacodynamics of \u03b2-lactams","volume":"27","author":"Turnidge","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.survophthal.2026.03.012_bib110","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1007\/s00018-004-4060-9","article-title":"Resistance to \u03b2-lactam antibiotics","volume":"61","author":"Poole","year":"2004","journal-title":"CMLS Cell Mol Life Sci"},{"issue":"3","key":"10.1016\/j.survophthal.2026.03.012_bib111","first-page":"189","article-title":"The challenge of patient adherence","volume":"1","author":"Martin","year":"2005","journal-title":"Ther Clin Risk Manag"},{"issue":"12","key":"10.1016\/j.survophthal.2026.03.012_bib112","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1097\/ICO.0000000000002680","article-title":"Medication adherence among patients with corneal diseases","volume":"40","author":"Khan","year":"2021","journal-title":"Cornea"},{"issue":"12","key":"10.1016\/j.survophthal.2026.03.012_bib113","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1080\/17512433.2023.2279740","article-title":"Determinants of adherence to treatment in patients with ophthalmic conditions","volume":"16","author":"Mu\u00f1oz-Villegas","year":"2023","journal-title":"Expert Rev Clin Pharm"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.012_bib114","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ogla.2019.01.006","article-title":"Factors affecting adherence to topical glaucoma therapy: a quantitative and qualitative pilot study analysis in Sydney, Australia","volume":"2","author":"Spencer","year":"2019","journal-title":"Ophthalmol Glaucoma"},{"issue":"9","key":"10.1016\/j.survophthal.2026.03.012_bib115","article-title":"Ocular light exposure interventions for sleep, circadian rhythms, rest-activity cycles, mood, and cognitive function in older adults","volume":"9","author":"Murukesu","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.survophthal.2026.03.012_bib116","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.molmed.2024.10.012","article-title":"Chronobiological and neuroendocrine insights into dry eye","volume":"31","author":"Li","year":"2025","journal-title":"Trends Mol Med"},{"issue":"7","key":"10.1016\/j.survophthal.2026.03.012_bib117","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/17425247.2023.2219053","article-title":"Sustained release ocular drug delivery systems for glaucoma therapy","volume":"20","author":"Al-Qaysi","year":"2023","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.survophthal.2026.03.012_bib118","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2147\/OPTH.S118409","article-title":"Systemic side effects of eye drops: a pharmacokinetic perspective","volume":"10","author":"Farkouh","year":"2016","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2026.03.012_bib119","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bcp.12268","article-title":"Formulations for children: problems and solutions","volume":"79","author":"Batchelor","year":"2015","journal-title":"Br J Clin Pharm"},{"issue":"3","key":"10.1016\/j.survophthal.2026.03.012_bib120","first-page":"171","article-title":"Pediatric dosing considerations in ophthalmology","volume":"13","author":"Patton","year":"1976","journal-title":"J Pedia Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib121","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ceo.13642","article-title":"New technique to reduce systemic side effects of timolol eye drops: the tissue press method\u2014Cross-over clinical trial","volume":"48","author":"M\u00fcller","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.03.012_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2022.109035","article-title":"Age-related ocular surface failure: a narrative review","volume":"219","author":"Di Zazzo","year":"2022","journal-title":"Exp Eye Res"},{"issue":"2","key":"10.1016\/j.survophthal.2026.03.012_bib123","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jconrel.2012.01.020","article-title":"The impact of ageing on the barriers to drug delivery","volume":"161","author":"Perrie","year":"2012","journal-title":"J Control Release"},{"issue":"10","key":"10.1016\/j.survophthal.2026.03.012_bib124","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1080\/1061186X.2024.2386626","article-title":"Geriatric drug delivery - barriers, current technologies and the road ahead","volume":"32","author":"Kean","year":"2024","journal-title":"J Drug Target"},{"issue":"5","key":"10.1016\/j.survophthal.2026.03.012_bib125","doi-asserted-by":"crossref","first-page":"352","DOI":"10.2165\/00002512-199711050-00003","article-title":"Systemic adverse effects of topical ophthalmic agents. Implications for older patients","volume":"11","author":"Diamond","year":"1997","journal-title":"Drugs Aging"},{"key":"10.1016\/j.survophthal.2026.03.012_bib126","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2174\/1874364101711010305","article-title":"A single drop in the eye - effects on the whole body?","volume":"11","author":"Vaajanen","year":"2017","journal-title":"Open Ophthalmol J"},{"issue":"6","key":"10.1016\/j.survophthal.2026.03.012_bib127","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0039-6257(93)90141-S","article-title":"Minimizing systemic absorption of topically administered ophthalmic drugs","volume":"37","author":"Urtti","year":"1993","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.03.012_bib128","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ajo.2023.05.007","article-title":"Risks of topical carbonic anhydrase inhibitors in glaucoma patients with chronic kidney disease","volume":"253","author":"Wang","year":"2023","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2026.03.012_bib129","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1742-7843.2011.00694.x","article-title":"Metabolism of ophthalmic timolol: new aspects of an old drug","volume":"108","author":"Volotinen","year":"2011","journal-title":"Basic Clin Pharm Toxicol"},{"issue":"1","key":"10.1016\/j.survophthal.2026.03.012_bib130","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/TP.0000000000002442","article-title":"Local delivery of regulatory T cells promotes corneal allograft survival","volume":"103","author":"Shao","year":"2019","journal-title":"Transplantation"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625726000457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625726000457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:48:39Z","timestamp":1784533719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625726000457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":130,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0039625726000457"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2026.03.012","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic principles behind eye drop dosing: From pharmacokinetics to clinical practice","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2026.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}